Frontida BioPharm Inc., a pharmaceutical Contract Development and Manufacturing Organization based in the Philadelphia and Chicago areas, has appointed Puneet Sapra as its new chief financial officer. Sapra will be replacing Andrew Wang, who recently accepted the CFO role at Frontage Holdings Corp., a CRO based in the U.S. and China.
 
Sapra joins Frontida with over 20 years of pharmaceutical and healthcare experience in executive roles at Pfizer Inc., Johnson & Johnson, Halma plc., and J.P. Morgan Chase & Co. His expertise in commercial, operational, and strategic finance comes with commendable notice as CFO of the Year from the Philadelphia Business Journal as well as industry leadership positions such as chairperson of the Pharmaceuticals Special Interest Group of Financial Executives Networking Group. Sapra is a graduate of Harvard Business School, Duke University and London School of Economics. 
 
Dr. Song Li, Frontida’s chairman, commented, “Mr. Sapra’s outstanding history in healthcare, strategic planning, capital raising, innovation, and transformative technology reflect highly on both his character as a leader and his professional repute within our industry. We are certain that Puneet will help Frontida advance our corporate growth strategy as we continue to expand and implement new technologies and products in our development and manufacturing operations.”
 
Sapra said, “I’m very excited to join Dr. Li and the entire team at Frontida. I share Frontida’s passion for advancing innovation in life sciences and I hope to use my skills to help accelerate Frontida’s exciting growth trajectory.”